局部晚期宫颈癌同步放化疗后18F-FDG PET/CT的预后价值及代谢反应预测因素
本回顾性研究纳入82例接受同步放化疗的局部晚期宫颈癌患者,治疗前后均行18F-FDG PET/CT,按EORTC标准分为完全代谢反应组(CMR)与非完全代谢反应组(N-CMR)。Kaplan-Meier分析显示两组总生存期差异高度显著(log-rank检验 P<0.0001)。治疗前MTV、TLG及淋巴结受累是治疗反应的预测因素,其中MTV预测价值最佳,但作者指出其额外风险价值似乎较低(MTV比值比=1.015)。
要点
- 治疗后18F-FDG PET/CT按EORTC标准评估的代谢反应可预测局部晚期宫颈癌同步放化疗患者的总生存期。
- 治疗前MTV、TLG及淋巴结受累是治疗反应的预测因素,MTV预测价值最佳。
- MTV的额外风险价值似乎较低(比值比=1.015)。
核心结论
- 基于18F-FDG PET/CT采用EORTC标准进行的治疗反应评估可可靠预测接受同步放化疗的局部晚期宫颈癌患者的总生存期。
- 在本研究队列中,治疗前MTV、TLG及淋巴结受累是治疗反应的预测因素。
- MTV是治疗反应的最佳预测因素,但其额外风险价值似乎较低(MTV比值比=1.015)。
研究设计与样本
- 回顾性研究,纳入82例接受同步放化疗的局部晚期宫颈癌患者。
- 所有患者治疗前后均行18F-FDG PET/CT,治疗后PET/CT按EORTC标准将患者分为完全代谢反应组(CMR)与非完全代谢反应组(N-CMR)。
- 采用Kaplan-Meier分析评估CMR组与N-CMR组总生存期差异,采用Student t检验、Pearson卡方检验及逻辑回归探究PET参数与临床参数作为治疗反应预测因素的价值。
主要发现
- Kaplan-Meier分析显示CMR组与N-CMR组总生存期差异高度显著(log-rank检验 P<0.0001)。
- 治疗反应的显著独立预测因素包括MTV(P=0.019,比值比=1.015,95%CI=1.002-1.028,Nagelkerke R2=0.110)。
- 治疗反应的显著独立预测因素包括TLG(P=0.045,比值比=1.001,95%CI=1.000-1.002,Nagelkerke R2=0.081)。
- 淋巴结受累为治疗反应的预测因素(P=0.088,比值比=2.361,95%CI=0.879-6.343,Nagelkerke R2=0.051)。
关键数值与推荐
- 治疗后PET/CT按EORTC标准分类为完全代谢反应(CMR)或非完全代谢反应(N-CMR)。
- MTV:P=0.019,比值比=1.015,95%CI=1.002-1.028,Nagelkerke R2=0.110。
- TLG:P=0.045,比值比=1.001,95%CI=1.000-1.002,Nagelkerke R2=0.081。
- 淋巴结受累:P=0.088,比值比=2.361,95%CI=0.879-6.343,Nagelkerke R2=0.051。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To investigate the prognostic value of posttreatment 18F-FDG PET/CT in patients with locally advanced cervical cancer (LACC) treated with concomitant chemoradiation therapy (CCRT). The secondary aim was to assess the possible role of intensity-based and volume-based PET parameters including SUVmax, SUVmean, MTV and TLG, and clinical parameters including age, pathology, FIGO stage and nodal involvement as factors predicting response to treatment. METHODS: This retrospective study included 82 patients affected by LACC treated with CCRT. All patients underwent 18F-FDG PET/CT both before and after treatment. The posttreatment PET/CT scans were used to classify patients as complete metabolic responders (CMR) or non-complete metabolic responders (N-CMR) according to the EORTC criteria. Kaplan-Meier analysis was used to evaluate differences in overall survival (OS) between the CMR and N-CMR groups. Student's t test, Pearson's chi-squared test and logistic regression were used to investigate the possible value of PET and clinical parameters as predictors of metabolic response to therapy. RESULTS: Kaplan-Meier analysis showed a highly significant difference in OS between the CMR and N-CMR groups (log-rank test p < 0.0001). Significant independent predictors of response to therapy were MTV (p = 0.019, odds ratio = 1.015, 95% CI = 1.002-1.028, Nagelkerke R2 = 0.110), TLG (p = 0.045, odds ratio = 1.001, 95% CI = 1.000-1.002, Nagelkerke R2 = 0.081) and nodal involvement (p = 0.088, odds ratio = 2.361, 95% CI = 0.879-6.343, Nagelkerke R2 = 0.051). CONCLUSION: 18F-FDG PET/CT-based response assessment using the EORTC criteria reliably predicts OS in LACC patients treated with CCRT. In our cohort of patients, pretreatment MTV and TLG and nodal involvement were predictors of response to therapy. MTV was the best predictor of response. However, its additional risk value seems to be low (MTV odds ratio = 1.015).
引用
- Lima GM, Matti A, Vara G, et al. Prognostic value of posttreatment 18F-FDG PET/CT and predictors of metabolic response to therapy in patients with locally advanced cervical cancer treated with concomitant chemoradiation therapy: an analysis of intensity- and volume-based PET parameters. Eur J Nucl Med Mol Imaging. 2018. PMID: 30069578. doi:10.1007/s00259-018-4077-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。